FDA Orange Book · active-ingredient family
Alogliptin benzoate; pioglitazone hydrochloride
Alogliptin benzoate; pioglitazone hydrochloride is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:OSENI · NDA 022426
1
Brand (NDA)
0
Generics (ANDA)
2
Listed patents
0
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| OSENIRLD×6 | TAKEDA PHARMS USA | NDA 022426 | — | Jan 25, 2013 |
Listed patents (2)
| Patent | Expires | In | Type |
|---|---|---|---|
| 7807689 | Jun 27, 2028 | in 2 yr 1 mo | SubstanceProductU-1337 |
| 8637079 | Jun 04, 2029 | in 3 yr | Product |
Alogliptin benzoate; pioglitazone hydrochloride — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
